ã容æã«å€ç°ããã³ãããŠã€ã«ã¹ã«å¯ŸããŠãã¹ãã€ã¯èçœãžã®æäœãèªå°ããã¯ã¯ãã³ãé »åã«æäžããããšã¯ãçæçã«ã¯å¹æãããããã«èŠããŠããäžé·æçã«ã¯å¹æãæžåŒ±ããã©ããããéå¹æã«ãããªãåŸãŸãããã®çŸè±¡ã¯æåå眪ãæäœäŸåæ§ææå¢åŒ·(Antibody dependent enhancement: ADE)ãšåŒã°ããåŸæ¥ãããŠã€ã«ã¹åŠãå
ç«åŠã§ã¯è¯ãç¥ãããŠãããã®ã§ãäžçäžã®èª å®ãªãŠã€ã«ã¹åŠè
ãå
ç«åŠè
ãèŠéã鳎ããç¶ããŠããŸããæåå眪ã®ãããªãã¯ãã³å€ç°äœã«å¯ŸããŠæå¹ãªã¯ã¯ãã³ã®å°å
¥ã¯å°é£ã§ãçŸè¡ã®ã¯ã¯ãã³ãæ¥çš®ãç¶ããŠãããšä»åŸãã€ADEãããããããªå€ç°äœãçŸããŠãããããã¯ãªããæ¥çš®ããã°ããã»ã©éå¹æã«ãªãå±éºæ§ãé«ãŸããšèããŸãã
2. mRNAã¯ã¯ãã³ã®å®å šæ§ã«å¯Ÿããæžå¿µ
ãmRNAã¯ã¯ãã³ã¯å®å šãªã¯ã¯ãã³ãšã¯èšããŸããã
ãmRNAã¯ã¯ãã³ã¯åŸæ¥ã®ã¯ã¯ãã³ãšã¯å šãéã£ãä»çµã¿ãå©çšãããã®ã§ãããæ¥çš®åŸã®é節ãªå¯åå¿ã®å ±åæ°ãåŸæ¥ã®ã¯ã¯ãã³ãšã¯æ¡éãã§ãäžé·æçãªå®å šæ§ã¯å šãäžæã§ãããä»åŸããŒã¹ã¿ãŒãç¶ããããšã§ããã«å±éºæ§ãå¢ããŠããå¯èœæ§ãé«ããšèããŸãã
ãmRNAã¯ã¯ãã³ã¯åœåãâ 泚å°éšäœã«çãŸããâ¡ããã«å解ããããâ¢ãŠã€ã«ã¹ã®äžéšãäœãããã ããªã®ã§å®³ããªãããšãã£ãçç±ã§å®å šãšãããŸãããããããã¯å šãŠééã£ãŠããããšãæããã«ãªã£ãŠããŸããã
2. mRNAã¯ã¯ãã³ã®å®å šæ§ã«å¯Ÿããæžå¿µ
ãmRNAã¯ã¯ãã³ã¯å®å šãªã¯ã¯ãã³ãšã¯èšããŸããã
ãmRNAã¯ã¯ãã³ã¯åŸæ¥ã®ã¯ã¯ãã³ãšã¯å šãéã£ãä»çµã¿ãå©çšãããã®ã§ãããæ¥çš®åŸã®é節ãªå¯åå¿ã®å ±åæ°ãåŸæ¥ã®ã¯ã¯ãã³ãšã¯æ¡éãã§ãäžé·æçãªå®å šæ§ã¯å šãäžæã§ãããä»åŸããŒã¹ã¿ãŒãç¶ããããšã§ããã«å±éºæ§ãå¢ããŠããå¯èœæ§ãé«ããšèããŸãã
ãmRNAã¯ã¯ãã³ã¯åœåãâ 泚å°éšäœã«çãŸããâ¡ããã«å解ããããâ¢ãŠã€ã«ã¹ã®äžéšãäœãããã ããªã®ã§å®³ããªãããšãã£ãçç±ã§å®å šãšãããŸãããããããã¯å šãŠééã£ãŠããããšãæããã«ãªã£ãŠããŸããã